CHUGAI PHARMACEUTICAL CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1925-03-10
- Employees
- 7.6K
- Market Cap
- $83.6B
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 144
- Registration Number
- NCT06723106
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺Campbelltown Public Hospital, Sydney, New South Wales, Australia
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 144
- Registration Number
- NCT06371417
- Locations
- 🇺🇸
University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 219
- Registration Number
- NCT05907980
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 184
- Registration Number
- NCT05735366
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸MUSC Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)
- Conditions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 12
- Registration Number
- NCT05686369
- Locations
- 🇺🇸
Science 37, Culver City, California, United States
Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis
- Conditions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 1000
- Registration Number
- NCT05433207
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 56
- Registration Number
- NCT05425446
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸Digestive Specialists Inc, Dayton, Ohio, United States
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 179
- Registration Number
- NCT05022927
- Locations
- 🇯🇵
Chiba University Hospital, Chiba-shi, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 195
- Registration Number
- NCT05012618
- Locations
- 🇺🇸
University of California - Davis, Davis, California, United States
🇺🇸Beth Israel Deaconess, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
An Observational Study of Patients With Endometriosis to Evaluate the Usefulness of the MEDL Score, a New Method for Evaluating Endometriosis Using MRI
- Conditions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 73
- Registration Number
- NCT04846582
- Locations
- 🇧🇷
Clinica Medicina da Mulher, São Sebastião, São Paulo, Brazil